Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHP465 6.25 mg in children with ADHD
NCT03325881Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing SHP465 with Placebo (2 arms). Primary endpoint: Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale-5 Total Score at 4 weeks. Started Dec 2017; status: completed.
02
Drugs
SHP465 mixed amphetamine salts
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03325881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03325881.